keyword
MENU ▼
Read by QxMD icon Read
search

PMBCL

keyword
https://www.readbyqxmd.com/read/29720487/metabolic-heterogeneity-on-baseline-18fdg-pet-ct-scan-is-a-predictor-of-outcome-in-primary-mediastinal-b-cell-lymphoma
#1
Luca Ceriani, Lisa Milan, Maurizio Martelli, Andrés J M Ferreri, Luciano Cascione, Pier Luigi Zinzani, Alice Di Rocco, Annarita Conconi, Anastasios Stathis, Franco Cavalli, Monica Bellei, Kelly Cozens, Elena Porro, Luca Giovanella, Peter W Johnson, Emanuele Zucca
An important unmet need in the management of primary mediastinal B-cell lymphoma (PMBCL) is to identify the patients for whom first line therapy will fail, in order to intervene before the lymphoma becomes refractory. High heterogeneity of intratumoral 18F-fluorodeoxyglucose (18FDG) uptake distribution on positron emission tomography/computed tomography (PET/CT) scans has been suggested as a possible marker of chemo-resistance in solid tumors. In the present study, we investigated the prognostic value of metabolic heterogeneity (MH) in 103 PMBCL patients prospectively enrolled in the International Extranodal Lymphoma Study Group (IELSG) 26 study, aimed at clarifying the role of PET in this lymphoma subtype...
May 2, 2018: Blood
https://www.readbyqxmd.com/read/29686956/management-of-primary-mediastinal-b-cell-lymphoma-in-pregnancy
#2
Sidra Khalid, Aariez Khalid, Hamed Daw, Praful Maroo
Primary mediastinal B-cell lymphoma (PMBCL) is a subtype of non-Hodgkin's lymphoma, which occurs rarely in pregnancy. We present a case of a pregnant 22-year-old female who presented with syncope and dyspnea. Computed tomography (CT) chest showed an anterior mediastinal mass, and its biopsy showed PMBCL. Since she was in her second trimester, we decided to treat her with rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). Our case emphasizes the safety of chemotherapy in the second and third trimesters, with good maternal and fetal outcomes...
February 21, 2018: Curēus
https://www.readbyqxmd.com/read/29672465/lactate-dehydrogenase-levels-and-18f-fdg-pet-ct-metrics-differentiate-between-mediastinal-hodgkin-s-lymphoma-and-primary-mediastinal-b-cell-lymphoma
#3
Rayan H M Alkhawtani, Walter Noordzij, Andor W J M Glaudemans, Rozemarijn S van Rijn, Hilde T van der Galiën, Hans Balink, Marcel Nijland, Hugo J A Adams, Gerwin Huls, Tom van Meerten, Thomas C Kwee
PURPOSE: This study aims to investigate whether clinical, laboratory, and fluorine-18-fluorodeoxyglucose (F-FDG) PET/CT findings can discriminate between mediastinal Hodgkin's lymphoma and primary mediastinal B-cell lymphoma (PMBCL). PATIENTS AND METHODS: This retrospective study included 56 patients (42 with mediastinal Hodgkin's lymphoma and 14 with PBMCL). Differences in clinical, laboratory, and F-FDG PET/CT metrics were assessed between Hodgkin's lymphoma and PMBCL...
June 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29660176/the-role-of-radiotherapy-as-salvage-and-or-consolidation-treatment-in-relapsed-refractory-and-high-risk-diffuse-large-b-cell-lymphoma
#4
Eric Grignano, Jérémy Laurent, Bénédicte Deau, Barbara Burroni, Didier Bouscary, Youlia M Kirova
OBJECTIVE: Many salvage therapies have been proposed for relapsed/refractory (R/R) diffuse large B-cell lymphomas or for consolidation in the case of suboptimal response. Radiotherapy (RT) is one modality of salvage therapy, but its place is currently not well defined. METHOD: This paper reports a retrospective review of patients receiving unplanned radiotherapy for R/R diffuse large B-cell lymphoma (DLBCL) or primary mediastinal B-cell lymphoma (PMBCL), or as consolidation therapy after second line chemotherapy, treated in our hospital...
April 16, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29655961/chimeric-antigen-receptor-t-cell-therapy-for-non-hodgkin-lymphoma
#5
REVIEW
Armin Ghobadi
Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy. More than 20,000 people in United States, more than 37,000 people in Europe and more than 199,000 people worldwide die of NHL every year. Recent advances in immunotherapeutic approaches for cancer have resulted in development of new classes of very effective immunotherapeutic approaches including chimeric antigen receptor T (CAR-T) cell therapy that are designed to bypass cancer immune evasion. Here, we review recent advances in CAR-T cell therapy for NHL...
April 11, 2018: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29467182/somatic-il4r-mutations-in-primary-mediastinal-large-b-cell-lymphoma-lead-to-constitutive-jak-stat-signaling-activation
#6
Elena Viganò, Jay Gunawardana, Anja Mottok, Tessa Van Tol, Katina Mak, Fong Chun Chan, Lauren Chong, Elizabeth Chavez, Bruce Woolcock, Katsuyoshi Takata, David Twa, Hennady P Shulha, Adèle Telenius, Olga Kutovaya, Stacy S Hung, Shannon Healy, Susana Ben-Neriah, Karen Leroy, Philippe Gaulard, Arjan Diepstra, Robert Kridel, Kerry J Savage, Lisa Rimsza, Randy Gascoyne, Christian Steidl
Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct subtype of diffuse large B-cell lymphoma thought to arise from thymic medullary B cells. Gene mutations underlying the molecular pathogenesis of the disease are incompletely characterized. Here, we describe novel somatic IL4R mutations in 15 of 62 primary cases of PMBCL (24.2%) and in all PMBCL-derived cell lines tested. The majority of mutations (11/21; 52%) were hotspot single nucleotide variants in exon 8, leading to an I242N amino acid change in the transmembrane domain...
May 3, 2018: Blood
https://www.readbyqxmd.com/read/29463854/autologous-stem-cell-transplantation-for-primary-mediastinal-b-cell-lymphoma-long-term-outcome-and-role-of-post-transplant-radiotherapy-a-report-of-the-european-society-for-blood-and-marrow-transplantation
#7
Irit Avivi, Ariane Boumendil, Hervé Finel, Arnon Nagler, Aïda Botelho de Sousa, Josep Maria Ribera Santasusana, Elizabeth Vandenberghe, Boris Afanasyev, Dominique Bordessoule, José Maria Moraleda, Eulogio Conde Garcia, David Pohlreich, Gonzalo Gutiérrez Garcia, Kirsty Thomson, Reuven Or, Dietrich Beelen, Eliana Zuffa, Sebastian Giebel, Christian Berthou, Gilles Salles, Angela Melpignano, Silvia Montoto, Peter Dreger
The purpose of this retrospective registry study was to investigate the outcome of autoSCT for primary mediastinal B-cell lymphoma (PMBCL) in the rituximab era, including the effects of eventual post-transplant radiotherapy (RT) consolidation. Patients with PMBCL aged between 18 and 70 years who were treated with a first autoSCT between 2000 and 2012 and registered with the EBMT were eligible. Eighty-six patients with confirmed PMBCL and the full data set required for this analysis were evaluable. Sixteen patients underwent autoSCT in remission after first-line therapy (CR/PR1), 44 patients were transplanted with chemosensitive relapsed or primary refractory disease (CR/PR >1), and 24 patients were chemorefractory at the time of autoSCT...
February 20, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29222270/primary-mediastinal-b-cell-lymphoma-biology-and-evolving-therapeutic-strategies
#8
REVIEW
Kieron Dunleavy
Primary mediastinal B-cell lymphoma (PMBCL) is recognized as a distinct clinicopathologic entity that predominantly affects adolescents and young adults and is more common in female subjects. Although PMBCL is considered to be a subtype of diffuse large B-cell lymphoma, its clinical, morphologic, and biological characteristics overlap significantly with those of nodular sclerosing Hodgkin lymphoma (NSHL). Over the past few years, the shared biology of these 2 entities has been highlighted in several studies, and mediastinal gray zone lymphoma, with features intermediate between PMBCL and NSHL, has been recognized as a unique molecular entity...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29082519/outcomes-of-adults-and-children-with-primary-mediastinal-b-cell-lymphoma-treated-with-dose-adjusted-epoch-r
#9
Lisa Giulino-Roth, Tara O'Donohue, Zhengming Chen, Nancy L Bartlett, Ann LaCasce, William Martin-Doyle, Matthew J Barth, Kimberly Davies, Kristie A Blum, Beth Christian, Carla Casulo, Sonali M Smith, James Godfrey, Amanda Termuhlen, Matthew J Oberley, Sarah Alexander, Sheila Weitzman, Burton Appel, Benjamin Mizukawa, Jakub Svoboda, Zeinab Afify, Melinda Pauly, Hema Dave, Rebecca Gardner, Deborah M Stephens, William A Zeitler, Christopher Forlenza, Jennifer Levine, Michael E Williams, Jody L Sima, Catherine M Bollard, John P Leonard
Treatment with dose-adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab (DA-EPOCH-R) has become the standard of care for primary mediastinal B-cell lymphoma (PMBCL) at many institutions despite limited data in the multi-centre setting. We report a large, multi-centre retrospective analysis of children and adults with PMBCL treated with DA-EPOCH-R to characterize outcomes and evaluate prognostic factors. We assessed 156 patients with PMBCL treated with DA-EPOCH-R across 24 academic centres, including 38 children and 118 adults...
December 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/29058502/axicabtagene-ciloleucel-a-first-in-class-car-t-cell-therapy-for-aggressive-nhl
#10
Zachary J Roberts, Marc Better, Adrian Bot, Margo R Roberts, Antoni Ribas
The development of clinically functional chimeric antigen receptor (CAR) T cell therapy is the culmination of multiple advances over the last three decades. Axicabtagene ciloleucel (formerly KTE-C19) is an anti-CD19 CAR T cell therapy in development for patients with refractory diffuse large B cell lymphoma (DLBCL), including transformed follicular lymphoma (TFL) and primary mediastinal B cell lymphoma (PMBCL). Axicabtagene ciloleucel is manufactured from patients' own peripheral blood mononuclear cells (PBMC) during which T cells are engineered to express a CAR that redirects them to recognize CD19-expressing cells...
October 23, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28935521/a-study-of-the-dosimetric-characteristics-between-different-fixed-field-imrt-and-vmat-in-early-stage-primary-mediastinal-b-cell-lymphoma
#11
Li-Ming Xu, Ming-Lei Kang, Bo Jiang, Qing-Feng Liu, Ye-Xiong Li
This analysis was designed to compare dosimetric parameters among different fixed-field intensity-modulated radiation therapy (IMRT) solutions and volumetric-modulated arc therapy (VMAT) to identify which can achieve the lowest risk of organs at risk (OARs) and treatment delivery efficiently. A total of 16 patients (8 male and 8 female) with early-stage primary mediastinal large B-cell lymphoma (PMBCL) were enrolled with planned gross tumor volume (PGTV) 45 Gy and planning target volume (PTV) 40 Gy. Four different plans were generated: 5-, 7, 9-field IMRT, and VMAT...
April 2018: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/28766543/-bone-marrow-involvement-in-primary-mediastinal-b-cell-lymphoma
#12
A U Magomedova, E A Fastova, A M Kovrigina, T N Obukhova, N I Skidan, Ya K Mangasarova, A I Vorobyev, S K Kravchenko
Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct type of large B-cell lymphoma. In this type of the disease, the neoplastic process is located in the anterior and superior mediastinum, frequently with compression of the superior vena cava and with tumor invasion into the adjacent organs and tissues: the pericardium, lung, pleura, etc. Despite the fact that in PMBCL progression, there may be involvement of extranodal organs, such as the kidney, adrenal glands, liver, and central nervous system, bone marrow (BM) injury is generally absent...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28634685/poor-predictive-value-of-positive-interim-fdg-pet-ct-in-primary-mediastinal-large-b-cell-lymphoma
#13
Julien Lazarovici, Marie Terroir, Julia Arfi-Rouche, Jean-Marie Michot, Sacha Mussot, Valentina Florea, Maria-Rosa Ghigna, Peggy Dartigues, Cynthia Petrovanu, Alina Danu, Christophe Fermé, Vincent Ribrag, David Ghez
PURPOSE: Though commonly used to assess response to therapy, the prognostic value of interim FDG-PET/CT in Primary Mediastinal Large B-cell Lymphoma (PMBCL) is unclear. METHODS: We conducted a retrospective study on 36 consecutive patients treated at our institution for a PMBCL between 2006 and 2014. All patients with a positive interim FDG-PET/CT had undergone histological restaging consisting either in a surgical debulking of the residual lesion (15 patients) or a CT-guided core needle biopsy (two patients)...
November 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28532396/addition-of-rituximab-to-chop-like-chemotherapy-in-first-line-treatment-of-primary-mediastinal-b-cell-lymphoma
#14
K Lisenko, G Dingeldein, M Cremer, M Kriegsmann, A D Ho, M Rieger, M Witzens-Harig
BACKGROUND: The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients. However, these results were obtained in young low risk patients and a reevaluation in an unselected patient cohort is warranted. METHODS: In this study, we analyzed 80 PMBCL patients treated with a CHOP-based regimen with and without rituximab. RESULTS: In the non-rituximab cohort 10-year progression free survival (PFS) was 67% and 10-year overall survival (OS) was 72% versus a PFS of 95% and a OS of 92% in the rituximab group, PFS P = 0...
May 22, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28490569/safety-and-tolerability-of-pembrolizumab-in-patients-with-relapsed-refractory-primary-mediastinal-large-b-cell-lymphoma
#15
MULTICENTER STUDY
Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, Jean-Marie Michot, John Kuruvilla, Arun Balakumaran, Yayan Zhang, Sabine Chlosta, Margaret A Shipp, Philippe Armand
Treatment options for relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) are limited, and prognosis is generally poor (overall response rate [ORR] 0% to 25%; 2-year overall survival 15%). PMBCL frequently involves PD-1 ligand overexpression, potentially making PMBCL particularly susceptible to PD-1 blockade. We evaluated safety and antitumor activity of pembrolizumab, an anti-PD-1 antibody, in rrPMBCL as part of the KEYNOTE-013 multicohort phase 1b trial. At time of data cutoff, 18 patients (median age 30 years; median 3 prior lines of therapy) had been enrolled and treated, of whom 17 were included in the efficacy analyses...
July 20, 2017: Blood
https://www.readbyqxmd.com/read/28179969/composite-lymphoma-opposite-ends-of-spectrum-meet
#16
Uqba Khan, Tarik Hadid, Warda Ibrar, Dahlia Sano, Ayad Al-Katib
An 18-year-old African-American female presented with an episode of syncope. Initial investigations revealed large lung mass with invasion into right atrium along with lesions in kidneys and liver. Patient also developed superior vena cava syndrome due to lung mass. Biopsy of lung mass revealed diagnosis of composite lymphoma with involvement by primary mediastinal B-cell lymphoma (PMBCL) and classical Hodgkin lymphoma. Patient was started on dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) with complete response to treatment...
March 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28144055/primary-mediastinal-lymphomas-their-morphological-features-and-comparative-evaluation
#17
Riti Aggarwal, Seema Rao, Shashi Dhawan, Sunita Bhalla, Arvind Kumar, Prem Chopra
BACKGROUND: Primary mediastinal lymphoma is an uncommon tumor. Hodgkin's lymphoma (HL), primary mediastinal B-cell lymphoma (PMBCL), and T-lymphoblastic lymphoma are the most common primary mediastinal lymphomas. Key morphological and immunohistochemistry (IHC) features play a very crucial role in diagnosis as well as further categorization. MATERIALS AND METHODS: In this study, the morphological spectrum and histological features of 32 cases of primary mediastinal lymphomas diagnosed over 5 years were studied and morphological and IHC features of PMBCL versus HL were compared...
January 2017: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/28078727/second-cancer-incidence-in-primary-mediastinal-b-cell-lymphoma-treated-with-methotrexate-with-leucovorin-rescue-doxorubicin-cyclophosphamide-vincristine-prednisone-and-bleomycin-regimen-with-or-without-rituximab-and-mediastinal-radiotherapy-results-from-a-monoinstitutional
#18
Vitaliana De Sanctis, Marco Alfò, Alice Di Rocco, Michela Ansuinelli, Eleonora Russo, Mattia F Osti, Maurizio Valeriani, Giuseppe Minniti, Lavinia Grapulin, Daniela Musio, Stefano Bracci, Alessandra Spagnoli, Maria Luisa Moleti, Vincenzo Tombolini, Maurizio Martelli
Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3...
December 2017: Hematological Oncology
https://www.readbyqxmd.com/read/27688726/primary-mediastinal-b-cell-lymphoma-metabolic-and-anatomical-features-in-18fdg-pet-ct-and-response-to-therapy
#19
Anna Kocurek, Bogdan Małkowski, Agnieszka Giza, Wojciech Jurczak
AIM OF THE STUDY: Determining the role of PET/CT imaging in the evaluation of treatment efficacy in primary mediastinal B-cell lymphoma (PMBCL). MATERIAL AND METHODS: Retrospective analysis of seven PMBCL patients, treated at the University Hospital in Krakow, with interim PET/CT after the third course of chemo-immunotherapy.The analysis was based on the calculation of exact tumour volume and metabolic activity, compared with initial values (directly after diagnosis)...
2016: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/27675775/utilization-of-positron-emission-tomography-computed-tomography-parameters-to-identify-patients-at-risk-for-progression-after-treatment-with-dose-adjusted-r-epoch-for-primary-mediastinal-b-cell-lymphoma-pmbcl
#20
C C Pinnix, Z Abou Yehia, W Qiao, S A Milgrom, G L Smith, M Akhtari, J Reddy, J R Gunther, E M Osborne, O R Mawlawi, L J Medeiros, N Garg, H H Chuang, S Neelapu, J R Westin, B Dabaja
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
100313
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"